Skip to main content
Premium Trial:

Request an Annual Quote

Pathway Diagnostics

Pathway Diagnostics has released the SensiTrop II assay, a new version of its SensiTrop assay that combines molecular heteroduplex tracking assay technology with molecular sequencing to determine the co-receptor tropism status of HIV-infected patients.
The company performs the assay in its CLIA-certified laboratory on samples received from national reference laboratories in the US and from Delphic Diagnostics in Europe.
Pathway said that it recently compared the performance of SensiTrop II with Monogram BiosciencesTrofile assay using 100 HIV treatment-experienced patient samples provided by Pfizer and previously tested by the Trofile assay. According to the company, SensiTrop II classified 41 samples as dual/mixed (D/M) tropic, while Trofile classified nine of these samples as R5-tropic. This number that is similar to the misclassification rate in Maraviroc's phase III data, Pathway said.
SensiTrop II is available through national reference laboratories and is also being used in CCR5 compound clinical trials, the company said.

Filed under

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.